Role of Inflammatory Markers in Sepsis
Sponsor
National Cancer Institute, Egypt (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06111963
Collaborator
(none)
60
1
10
6
Study Details
Study Description
Brief Summary
A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
60 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Role of Inflammatory Markers Measured Using Flow Cytometry in the Diagnosis and Prognosis of Sepsis in Surgical Cancer Patients
Anticipated Study Start Date
:
Oct 1, 2023
Anticipated Primary Completion Date
:
Jul 1, 2024
Anticipated Study Completion Date
:
Aug 1, 2024
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Septic patients
|
Diagnostic Test: Serology tests
CD4, CD25, IL17
|
| Non Septic patients
|
Diagnostic Test: Serology tests
CD4, CD25, IL17
|
Outcome Measures
Primary Outcome Measures
- To evaluate the expression CD4 [7 days]
Serology
- To evaluate the expression CD25 [7 days]
Serology
- To evaluate the expression IL17 [7 days]
Serology
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis
Exclusion Criteria:
-
Refusal of patient or patient guardian to participate.
-
Intraoperative massive blood loss and massive blood transfusion
-
Patients with impaired preoperative kidney or liver function tests
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Walaa Y Elsabeeny | Cairo | Egypt | 11796 |
Sponsors and Collaborators
- National Cancer Institute, Egypt
Investigators
- Principal Investigator: Walaa Y Elsabeeny, MD, National Cancer Institute, Cairo University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Walaa Youssef Elsabeeny,
Assistant Professor of Anesthesia and Pain management,
National Cancer Institute, Egypt
ClinicalTrials.gov Identifier:
NCT06111963
Other Study ID Numbers:
- AP2305-301-001
First Posted:
Nov 1, 2023
Last Update Posted:
Nov 1, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: